Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first line of after failure to first line systemic or liver directed therapy.
Uveal Melanoma|Metastatic Cancer
DRUG: Cediranib Maleate|DRUG: Durvalumab
Objective response rate by RECIST 1.1, ORR calculated as the proportion of patient with a complete response (CR) or partial response (PR). The final statistical analysis of this endpoint is expected to be performed every 8 weeks since start of treatment., 24 months after start of treatment
Median Progression-free survival (PFS) by RECIST 1.1, Median time between start of treatment and date of progression of disease, 24 months after start of treatment|Overall Survival Rate at 12 months, Proportion of patients alive 12 months since start of treatment, 12 months after start of treatment|Overall Survival Rate at 24 months, Proportion of patients alive 24 months since start of treatment, 24 months after start of treatment|Increase in effector CD8 T-cell response in the tumor induced by cediranib combined with durvalumab, Changes in the CD8 values from baseline, 24 months after start of treatment|Number of participants with adverse events as assessed by CTCAE v5.0, 24 months|Number of participants with serious adverse events as assessed by CTCAE v5.0, 24 months|Number of participants with immune-related adverse events as assessed by CTCAE v5.0, 24 months|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, 24 months
Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first line of after failure to first line systemic or liver directed therapy.